Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 3.7%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares were down 3.7% on Monday . The company traded as low as $0.43 and last traded at $0.43. Approximately 29,671 shares were traded during trading, a decline of 68% from the average daily volume of 93,100 shares. The stock had previously closed at $0.45.

Theriva Biologics Price Performance

The company has a market capitalization of $7.55 million, a price-to-earnings ratio of -0.38 and a beta of 1.45.

Institutional Investors Weigh In On Theriva Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in TOVX. BlackRock Inc. bought a new position in shares of Theriva Biologics in the 1st quarter valued at approximately $133,000. Geode Capital Management LLC bought a new position in shares of Theriva Biologics in the 1st quarter valued at approximately $81,000. Finally, Citadel Advisors LLC bought a new position in shares of Theriva Biologics in the 4th quarter valued at approximately $25,000. 6.17% of the stock is owned by hedge funds and other institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.